Via Nova Therapeutics, an Oakland, Calif.-based company established to discover and develop therapeutics for acute and subacute viral infections, closed raised $20m and closed its Series A financing.
Aditum Bio made the investment.
The company intends to use the funds to advance the development of four preclinical antiviral programs in-licensed from Novartis.
Founded by virologists Don Ganem, MD and Kelly Wong, PhD, Via Nova was established to discover and develop therapeutics for acute and subacute viral infections for which current treatments are lacking or inadequate. The current programs were part of an antiviral portfolio led by the founders while at Novartis and target several important respiratory viruses (including influenza viruses, adenoviruses and rhinoviruses) as well as human polyomaviruses, which produce severe disease in immunocompromised hosts. The company targets fundamental mechanisms of viral replication and accordingly can support discovery of novel therapeutics for other viral infections as well.
FinSMEs
08/09/2021